China's WuXi Biologics will likely produce COVID-19 vaccines in Germany by the end of the year, according to local media Saturday.

The Chinese pharmaceutical company last December struck a 150-million-euro ($183.3 million) deal with global chemicals giant Bayer to take over its drug substance manufacturing facility in Wuppertal.

WuXi Biologics will take over the facility in a matter of a few weeks and may produce COVID-19 vaccine and active ingredients of other biological products in December after getting approval from authorities.